Cargando…

Extraordinarily elevated CD33 expression in CD56(+)CD3(–) cells in the bone marrow of a patient with relapsed acute myeloid leukemia: a case report

Based on genetic risk allogeneic stem cell transplantation (allo-SCT) is the only curative treatment for some forms of acute myeloid leukemia (AML). However, post-transplantation relapse remains a frequent cause of transplantation failure. Natural killer (NK) cells and CD8+ T cells are important eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Dongyao, Geng, Liangquan, Liu, Huilan, Fang, Yongjun, Sun, Zimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798139/ https://www.ncbi.nlm.nih.gov/pubmed/35116354 http://dx.doi.org/10.21037/tcr-21-733

Ejemplares similares

Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
por: Aref, Salah, et al.
Publicado: (2020)

Targeting CD33 for acute myeloid leukemia therapy
por: Liu, Jingjing, et al.
Publicado: (2022)

Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
por: Zheng, Changcheng, et al.
Publicado: (2017)

Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
por: Liang, Tianqi, et al.
Publicado: (2022)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Almeida, Jani-Sofia, et al.
Publicado: (2019)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
por: Farge, Thomas, et al.
Publicado: (2023)

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia
por: Alegretti, Ana Paula, et al.
Publicado: (2011)

The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia
por: Rego, Eduardo Magalhães
Publicado: (2011)

CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells
por: Nakatsugawa, Munehide, et al.
Publicado: (2016)

The osteogenic commitment of CD271+CD56+ bone marrow stromal cells (BMSCs) in osteoarthritic femoral head bone
por: Ilas, Dragos C., et al.
Publicado: (2020)

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33(+) Acute Myeloid Leukemia
por: Dutour, A., et al.
Publicado: (2012)

The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia
por: Tran, Vinh Thanh, et al.
Publicado: (2020)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Alterations in the CD56(−) and CD56(+) T Cell Subsets during COVID-19
por: Vavilova, Julia D., et al.
Publicado: (2023)

Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells
por: Xu, Qianwen, et al.
Publicado: (2022)

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
por: Laszlo, George S., et al.
Publicado: (2016)

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022)

Immunosuppressive role of CD11b(+)CD33(+)HLA‐DR(−) myeloid‐derived suppressor cells‐like blast subpopulation in acute myeloid leukemia
por: Hyun, Shin Young, et al.
Publicado: (2020)

CD56(dim)CD57(+)NKG2C(+) NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT
por: Cichocki, Frank, et al.
Publicado: (2015)

Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg(®)) in children with relapsed/refractory myeloid leukemia
por: Brethon, Benoit, et al.
Publicado: (2006)

Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms
por: Thiago, Leandro S., et al.
Publicado: (2013)

Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia
por: Malagola, Michele, et al.
Publicado: (2023)

The Function of CD3(+)CD56(+) NKT-Like Cells in HIV-Infected Individuals
por: Jiang, Yongjun, et al.
Publicado: (2014)

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
por: Mamolo, Carla, et al.
Publicado: (2020)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
por: Molica, Matteo, et al.
Publicado: (2021)

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation with the CD34(+)/CD38(-) population
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Repression of phagocytosis by human CD33 is not conserved with mouse CD33
por: Bhattacherjee, Abhishek, et al.
Publicado: (2019)

Bone marrow CD3 (+) CD56 (+) regulatory T lymphocytes (T(R3) (−56) cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS‐R very‐low/low risk MDS patients
por: Leone, Stefania, et al.
Publicado: (2022)

Acute Myeloid Leukemia With MLL Rearrangement and CD4+/CD56+ Expression can be Misdiagnosed as Blastic Plasmacytoid Dendritic Cell Neoplasm: Two Case Reports
por: Lee, Ju-Mee, et al.
Publicado: (2016)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

CD56(dim)CD16(high) and CD56(bright)CD16(−) cell percentages associated with maximum knee extensor strength and incidence of death in elderly
por: Senpuku, Hidenobu, et al.
Publicado: (2016)

Diagnostic confusion resulting from CD56 expression by cutaneous myeloid sarcoma
por: Ho, Thanh, et al.
Publicado: (2009)

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
por: Boyiadzis, Michael, et al.
Publicado: (2023)

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19(+) CD33(+) leukemia cells
por: Roskopf, Claudia C., et al.
Publicado: (2016)

Local CD4+, CD8+ and CD56+ T-lymphocite Reaction on Primary Lung Cancer
por: Jusufovic, Edin, et al.
Publicado: (2011)

What is CD4+CD56+ malignancy and how should it be treated?
por: Reimer, P, et al.
Publicado: (2003)

Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary
por: Völker, Hans-Ullrich, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_bo4kirb6fsdh9ei8pri80gqf0q